We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Protein-free, animal component-free, chemically defined cryopreservation medium
Designed to maintain viability and maximize efficiency for preserving cells in today’s advanced applications.
Accelerate life-changing therapies to market: Now available as an excipient and non-excipient medium
The cutting-edge formulations of PRIME-XV FreezIS Cryopreservation Media Portfolio are optimized to protect and preserve cells without compromising functionality no matter how manufacturing needs change.
Meet with our team of cell culture media experts to determine the right PRIME-XV formulation for manufacturing success.
Product | Customer use | Contains DMSO | DMSO-free | Eliminates post-thaw wash step | Reduces vein-to-vein time |
PRIME-XV FreezIS | Ancillary | ✓ | |||
PRIME-XV FreezIS DMSO-Free | Ancillary | ✓ | |||
PRIME-XV FreezIS (EX) | Excipient | ✓ | ✓ | ✓ | |
PRIME-XV FreezIS DMSO-Free (EX) | Excipient | ✓ | ✓ | ✓ |
*Excipient products are for research or further manufacturing use only. Not for injection as a standalone product or diagnostic procedures. Product can be used as excipient, which means that the cells and media combined are treated as one product that is to be approved by the FDA. Testing for individual applications is the responsibility of the customer.
**Non-excipient products are for research or further manufacturing use only. Not for injection or diagnostic procedures. Testing for individual applications is the responsibility of the customer.
Figure 1. PRIME-XV FreezIS supports high post-thaw viability of MSCs. Human adipose-derived mesenchymal stromal/stem cells (MSCs) had high plating efficiency (A) and viability (B) 24 hours post-thaw after cryopreservation in PRIME-XV FreezIS compared to a commercially-available cryopreservation solution. Images were taken at 10X magnification.
Figure 2. PRIME-XV FreezIS supports cryopreservation and recovery of PBMCs. (A) Fresh human peripheral blood mononuclear cells thawed and cultured for 13 days yielded 100-fold expansion. (B) PBMCs thawed from PRIME-XV FreezIS showed a slightly higher viability at thaw and maintained a viability above 85% over the 13 days in culture. (C) Cell diameter increases post-thaw as the cells recover from the cryopreservation, returning to baseline 24 hours later. Cell diameter is highest at the peak of the exponential growth phase around Day 7 and returns to baseline again at the end of expansion.
Manufactured to facilitate transfer from research to clinic with robust raw material controls and supply chain management support
Custom sizes and packaging available upon request.
Contact us for international pricing and custom formulations.